Stemline

YTD

ALL

Why Robinhood?

You can watch Stemline and buy or sell other stocks, options, and ETFs commission-free!

About STML

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company and a leading developer of novel oncology compounds directed to cancer stem cell targets. Stemlineâ€™s lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells.

CEO

Ivan Bergstein, MD

CEOIvan Bergstein, MD

Employees

—

Employees—

Headquarters

New York, New York

HeadquartersNew York, New York

Founded

2003

Founded2003

Employees

—

Employees—

STML Key Statistics

Market cap

621.20M

Market cap621.20M

Price-Earnings ratio

-7.47

Price-Earnings ratio-7.47

Dividend yield

—

Dividend yield—

Average volume

2.51M

Average volume2.51M

High today

—

High today—

Low today

—

Low today—

Open price

—

Open price—

Volume

0.00

Volume0.00

52 Week high

$18.22

52 Week high$18.22

52 Week low

$3.21

52 Week low$3.21